J

Johnson & Johnson

Makes prescription drugs and medical devices

Key Account Manager Immunology

Full-TimeUpdated on 10/16/2026Deadline 10/26/26
PLN156k - PLN250.7k+ Annual bonus + Sales commissions
Mid
Bachelor's
Łódź, Poland
HybridDaily travel within the allocated territory is required.
Sales & Account ManagementField Sales

About the job

Requirements
  • A university degree is required.
  • At least 3 years of experience in pharmaceutical sales is required, including experience with specialty care and the hospital market involving NFZ drug programs.
  • Strong communication and negotiation skills are required.
  • The ability to make strategic decisions and take ownership of outcomes is required.
  • Openness and readiness to implement new business solutions are required.
  • A customer- and action-oriented approach is required.
  • Strong organizational skills are required.
  • Good spoken and written English and knowledge of the local language are required.
  • Fluent use of Microsoft Office is required.
  • The ability to facilitate virtual meetings using platforms such as Zoom and Microsoft Teams is required.
  • An active category B driving license is required.
  • Availability to travel daily within the allocated territory is required.
  • The employee must comply with HCC and HCBI procedures, internal procedures, expense-settlement rules, quality requirements, and company standard operating procedures.
  • Compulsory training must be completed on time, and activities and quality defects must be reported in a timely and compliant manner.
  • Only approved products may be promoted, based on the approved marketing strategy.
  • The employee must maintain ethical standards, quality, compliance, and accountability, and help others do the same when appropriate.
  • The employee must take care of company property and maintain the proper technical condition of company equipment, such as a car, telephone, and computer.
Responsibilities
  • Present and promote assigned products to healthcare practitioners and other stakeholders in assigned territories, in compliance with ethical rules and approved marketing and sales strategies.
  • Communicate appropriate therapeutic information about approved products to healthcare practitioners in accordance with the approved marketing strategy.
  • Achieve allocated performance targets for product sales, market share, customer coverage and visit frequency, and multichannel activities.
  • Build a professional company image; identify, develop, and finalize promotional opportunities; and build and maintain trusting relationships with customers and collaborators.
  • Identify and analyze opportunities and problems, and propose appropriate improvements.
  • Organize promotional events in accordance with the approved marketing strategy and compliance and ethical rules.
  • Act as a subject-area expert and create awareness of patient journeys, unmet needs, and therapeutic-area topics.
  • Manage the territory through strategic planning based on available data, adapting tools and activities to the local market to achieve business goals.
  • Collaborate with Marketing, Medical, and Access stakeholders to develop key account plans and objectives and share responsibilities.
  • Evaluate progress against plans monthly and make tactical, strategic, and longer-term course corrections in collaboration with the manager.
  • Analyze reports from organizations on sales of the company's products and market shares, and draw conclusions.
  • Establish strong relationships with healthcare practitioners in the assigned territory.
  • Establish multichannel stakeholder communications.
  • Provide product and sales management with regular input on strategy implementation and competitor activity.
  • Learn from new experiences, take action to improve continuously, share best practices, and drive innovation for customers.
  • Manage the entrusted budget.
  • Support procurement processes in hospitals.
  • Deliver administrative work accurately and on time.
  • Ensure promotional visits and other promotional activities are effective and meet quality standards.
  • Use open communication and feedback, and participate actively in meetings.
  • Respond proactively to market situations, seek solutions, make decisions, and take responsibility for them.
  • Collaborate with team members to accomplish assigned tasks.
  • Develop oneself and others, engage in open and honest conversations, and drive performance by managing energy and taking ownership of outcomes.
Desired Qualifications
  • Preferred skills include business development, clinical experience, communication, cross-functional collaboration, customer centricity, customer retention, data savvy, partnership development, immunology, market knowledge, performance measurement, pharmaceutical industry knowledge, pharmaceutical sales marketing, problem solving, product knowledge, relationship building, sales, sales projections, sales trend analysis, and strategic sales planning.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.